Hangzhou Tigermed Consulting Co., Ltd. Class A

Hangzhou Tigermed Consulting Co., Ltd. Class A

4.10
EUR
-0.02
(-0.49%)
-0.06EPS
7.04BMarket Cap
Mar 29Next Earn

Total Valuation

EUR

As of September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H carries a market capitalization of 7.04B, placing it among publicly traded companies globally. Its enterprise value stands at 7.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.04B
Enterprise Value7.53B

Important Dates

Hangzhou Tigermed Consulting Co., Ltd. Class H's next confirmed earnings release is scheduled for March 29, 2027.

Earnings Date3/29/2027

Share Statistics

As of September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H has 1.32B shares outstanding.

Shares Outstanding1.32B

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 5.05, and the price-to-book ratio stands at 2.72.

PS Ratio5.05
PB Ratio2.72
P/TBV Ratio3.35

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 7.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.53B versus a market cap of 7.04B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.53

Financial Position

As of September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H maintains a current ratio of 2.54, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Current Ratio2.54
Quick Ratio0.79
Debt / Equity9.53
Debt / EBITDA-10.69

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H posted a negative return on equity (ROE) of -2.01, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.43, reflecting losses generated across the asset base. The company generates approximately 89,848.89 in revenue per employee across its workforce of 11,130.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 105.17 indicates how many times Hangzhou Tigermed Consulting Co., Ltd. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-2.01
Return on Assets (ROA)-1.43
Revenue Per Employee89,848.89
Employee Count11,130.00
Inventory Turnover105.17

Taxes

EUR

Over the twelve months ended September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H recorded 26.45M in income tax expense. The company reported a pretax loss of -27.59M and -53.25M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax26.45M

Stock Price Statistics

EUR

As of the close on November 17, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H's stock has declined approximately 9.29% over the past 52 weeks. The 50-day moving average sits at 4.75, while the 200-day moving average is 4.43.

52-Week Price Change-9.29%
50-Day Moving Average4.75
200-Day Moving Average4.43

Income Statement

EUR

Over the twelve months ended September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H generated 1.00B in revenue and converted that into -53.25M in net income, yielding earnings per share of -0.06. EBITDA reached -27.30M, while operating income came in at 101.09M.

Revenue1.00B
Gross Profit262.10M
Operating Income101.09M
Pretax Income-27.59M
Net Income-53.25M
EBITDA-27.30M
EBIT-27.30M
Earnings Per Share (EPS)-0.06

Balance Sheet

EUR

As of September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H holds 278.79M in cash and equivalents against 291.88M in total debt, resulting in a net debt position of -41.04M. Total book value stands at 2.58B, with working capital of 545.95M providing operational flexibility.

Cash & Cash Equivalents278.79M
Total Debt291.88M
Net Debt-41.04M
Equity (Book Value)2.58B
Book Value Per Share1.96
Working Capital545.95M

Cash Flow

EUR

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-22.63M

Margins

Over the twelve months ended September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H posted a gross margin of 26.21, reflecting its pricing power and cost economics. The operating margin of 10.11 and net profit margin of -5.32 provide insight into operational efficiency.

Gross Margin26.21
Operating Margin10.11
Pretax Margin-2.76
Profit Margin-5.32
EBITDA Margin-2.73

Dividends & Yields

EUR

Over the twelve months ended September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H paid dividends of 0.03 per share. The dividend payout ratio of -46.73 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hangzhou Tigermed Consulting Co., Ltd. Class H shareholders.

Dividend Per Share0.03
Payout Ratio-46.73
Shareholder Yield1.09

Scores

As of September 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H has an Altman Z-Score of 7.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.93